Novavax Inc Stock Price, News & Analysis

Novavax, Inc. (Nasdaq: NVAX) has entered into an Advance Purchase Agreement with the New Zealand government for 10.7 million doses of its COVID-19 vaccine candidate, NVX-CoV2373. The vaccine, currently in Phase 3 clinical trials in the UK, utilizes Novavax's proprietary Matrix-M™ adjuvant to boost immune response. Initial deliveries are targeted for mid-2021, pending regulatory approvals. Novavax aims to ensure vaccine accessibility for New Zealanders, reflecting confidence in its candidate amid the ongoing pandemic.

Novavax, Inc. (Nasdaq: NVAX) has appointed Margaret G. McGlynn, R. Ph., as an independent director on its board. McGlynn brings significant experience in vaccine commercialization and public health, which will be crucial as Novavax approaches the Phase 3 data collection for its COVID-19 vaccine candidate, NVX-CoV2373. With a strong background from the International AIDS Vaccine Initiative and Merck, she aims to bolster Novavax's mission to distribute the vaccine globally. Currently, Novavax is also advancing its quadrivalent influenza nanoparticle vaccine.

Novavax, Inc. (Nasdaq: NVAX) has announced significant progress in its COVID-19 vaccine program, NVX-CoV2373. The pivotal Phase 3 trial in the U.K. is fully enrolled with 15,000 participants, while the Phase 2b trial in South Africa has also completed enrollment with 4,422 participants. A Phase 3 trial in the U.S. and Mexico is set to commence soon. The company has garnered $1.6 billion in funding from the U.S. government and anticipates interim data from these trials in early 2021, potentially supporting global regulatory applications.

Novavax (Nasdaq: NVAX) announced participation in two investor conferences to discuss its COVID-19 vaccine candidate, NVX-CoV2373. The first is the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 2020, featuring a panel discussion moderated by Edward A. Tenthoff and Yasmeen Rahimi, with Dr. Gregory M. Glenn as a panelist. The second event is the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020, which includes a fireside chat and investor meetings. NVX-CoV2373 is currently in various stages of clinical trials and has secured $2 billion in funding for its vaccine program.

Novavax is set to host a live Q&A conference call on November 10, 2020, due to technical difficulties during its quarterly earnings call on November 9. The session invites the investment community to discuss the Company's third-quarter financial and operational results. The call will commence at 4:30 p.m. ET, following the close of U.S. financial markets, with details available on Novavax's website. A replay will be accessible until November 17, 2020.

Novavax (NVAX) reported a net loss of $197.3 million for Q3 2020, significantly higher than the $18 million loss in Q3 2019. Revenue reached $157 million, boosted by funding for NVX-CoV2373, its COVID-19 vaccine candidate, which has entered a Phase 3 trial in the U.K. with 15,000 participants. The company secured over $2 billion in funding from various sources for clinical development. Manufacturing capacity for NVX-CoV2373 is set to exceed two billion doses by mid-2021. Novavax is also advancing its NanoFlu program with a new leadership team.

Novavax, a late-stage biotechnology firm, has announced leadership changes aimed at enhancing its commercialization strategy. Gregory F. Covino joins as CFO, bringing extensive global financial expertise. John Trizzino shifts from CFO to Chief Commercial Officer to focus on advancing the COVID-19 vaccine candidate NVX-CoV2373 and NanoFlu. Filip Dubovsky is promoted to Executive Vice President and Chief Medical Officer, while Biegie Lee becomes Senior Vice President and Chief Information Officer.

These changes are crucial as Novavax prepares to enter global markets with its promising vaccine candidates.

Novavax (Nasdaq: NVAX) has received Fast Track Designation from the FDA for its COVID-19 vaccine candidate, NVX-CoV2373. This designation aims to expedite the development and regulatory review process, highlighting the urgent need for an effective vaccine. The Phase 3 clinical trial in the U.S. and Mexico is expected to begin by the end of November 2020, with interim data anticipated from the UK trial in early 2021. Novavax has secured $2 billion in funding for its global vaccine program.

Novavax, a late-stage biotechnology company, signed a non-binding Heads of Terms with the Australian Government to supply 40 million doses of its COVID-19 vaccine candidate, NVX-CoV2373. The arrangement aims to provide access to the vaccine, pending successful Phase 3 trials and approval by the Therapeutic Goods Administration. Initial deliveries are expected in the first half of 2021. Notably, Australia has contributed to clinical trials, enhancing the vaccine's development, while Novavax has secured $2 billion in funding for its global vaccine program.